8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Jan 30, 2026·SEC
OmniAb, Inc.(OABI)Earnings, Financials & Key Ratios
OABI•NASDAQ
$2.32
Price updated Jul 7, 2026
AboutOmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.Show more
- Revenue$19M-29.3%
- EBITDA-$50M+2.3%
- Net Income-$65M-4.4%
- EPS (Diluted)-0.57+6.6%
- Gross Margin-18.17%-118.2%
- EBITDA Margin-266.6%-38.2%
- Operating Margin-383.15%-35.7%
- Net Margin-347.04%-47.6%
- ROE-23.36%-13.4%
OABI Price & Volume
OmniAb, Inc. (OABI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Milestone Volatility Strains Operational Liquidity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Rapid Cash Reserve Depletion
Key Thesis Takeaways
- OmniAb's reliance on lumpy, milestone-driven revenue creates significant unpredictability, as evidenced by the 2.5% growth rate in 2026Q1 following multiple periods of sharp contraction.
- While the company maintains a unique transgenic platform, the persistent net losses and the erosion of total assets from $375.2 million in 2023Q4 to $293.6 million in 2026Q1 suggest a structural inability to cover high R&D expenditures.
- Investors should monitor the $84.0 million goodwill balance and the precarious $29.0 million cash position, which may necessitate further capital raises if royalty streams fail to scale.
Verdict Logic
the company's inability to achieve consistent profitability, coupled with a rapid depletion of cash reserves to $29.0 million, presents a high risk of further equity dilution.
OABI Growth Metrics
OmniAb, Inc. (OABI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-4.31%
3 Years-31.89%
TTM8.11%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.69%
Return on Capital
10 Years-14.31%
5 Years-17.11%
3 Years-21.7%
Last Year-24.03%
OABI Recent Earnings
OmniAb, Inc. (OABI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.06+40.0%
$0.10
Rev
$14M+157.6%
$6M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.11-37.5%
$0.08
Rev
$8M-7.0%
$9M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.14-2.9%
$0.14
Rev
$2M-60.3%
$6M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.15-7.1%
$0.14
Rev
$4M-31.0%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.06vs $0.10+40.0% | $14Mvs $6M+157.6% |
| Q2 2026 | Mar 4, 2026 | $0.11vs $0.08-37.5% | $8Mvs $9M-7.0% |
| Q4 2025 | Nov 4, 2025 | $0.14vs $0.14-2.9% | $2Mvs $6M-60.3% |
| Q3 2025 | Aug 6, 2025 | $0.15vs $0.14-7.1% | $4Mvs $6M-31.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for OmniAb, Inc. (OABI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.32 | $276.29M | -4.07 | -29.27% | -347.04% | -23.36% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $1.35 | $171.71M | -1.21 | 14.85% | -173.02% | — | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $676.23 | $70.26B | 16.30 | 0.99% | 29.65% | 14.32% | — |
Compare OABI vs Peers
OmniAb, Inc. (OABI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OABI SEC Filings & Documents
OmniAb, Inc. (OABI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OABI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OABI Frequently Asked Questions
OmniAb, Inc. (OABI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is OmniAb, Inc.'s revenue?
OmniAb, Inc. (OABI) reported $28.9M in revenue for fiscal year 2025. This represents a 58% increase from $18.3M in 2019.
How fast is OmniAb, Inc. growing?
OmniAb, Inc. (OABI) saw revenue decline by 29.3% over the past year.
Is OABI profitable?
OmniAb, Inc. (OABI) reported a net loss of $54.3M for fiscal year 2025.
Dividend & Returns
What is OABI's return on equity?
OmniAb, Inc. (OABI) has a return on equity (ROE) of -23.4%. Negative ROE indicates the company is unprofitable.
What is OmniAb, Inc.'s free cash flow?
OmniAb, Inc. (OABI) had negative free cash flow of $26.0M in fiscal year 2025, likely due to heavy capital investments.